Newsletter | February 9, 2021

02.09.21 -- Business Of Biotech Introduces The Cell And Gene Series - New Episodes Out Now!

Listen Now: Our Latest Podcast Episodes

Check out the latest from Business of Biotech and Life Science Connect. As a member of the Life Science Connect community you have access to content beyond our weekly newsletters, including our podcast series. Don’t forget to subscribe so that you never miss an episode!


Keeping Cell Therapy Clinicals On The Rails With Brian Culley

On the latest episode of Business of Biotech, Lineage Cell Therapeutics CEO, Brian Culley, explains how he kept the company's programs for OpRegen® (dry AMD with GA) and OPC1 (acute spinal cord injury) running on time despite the disruptions of a global pandemic.

Orchard Tx's Bobby Gaspar On Manufacturing Hematopoietic Stem Cells

Continuing our Cell & Gene Series, Business of Biotech features Dr. Bobby Gaspar, Orchard Therapeutics CEO, speaking on the challenges his company faces in the production of hematopoietic stem cells to treat neurometabolic disorders, primary immune deficiencies, and blood disorders.

Acepodia's Approach To ACC And CAR Manufacturing Scalability

Acepodia's Dr. Sony Hsiao, CEO, and Dr. Mark Gilbert, SVP of R&D, join Business of Biotech for a discussion on the company's approach to dramatically reducing the cost of cell therapy development, manufacturing, and administration via its oNK, CAR, and ACC candidates.

The AAV Vector Challenge With Selecta's Dr. Carsten Brunn

Business of Biotech’s Cell & Gene Miniseries opens with Dr. Carsten Brunn, president and CEO of Selecta Biosciences. Guest host Erin Harris joins our discussion on Selecta's ImmTOR platform and how the company is addressing the immunogenicity of adeno-associated virus (AAV) vectors challenge faced by gene therapy companies.

A Look Behind, A Look Ahead With Allan Shaw

Business of Biotech kicks off the new year with an up-close-and-personal talk with biotech investor and CFO extraordinaire Allan Shaw. We talk through last year's ups and downs and do a little prognosticating on what we're feeling bullish about — from unprecedented regulatory action to exciting progress on the cell and gene front — as we head into the new year.


Perceptions Of A Virtual JPM

Rob Wright, Life Science Leader’s chief editor, has attended numerous JPM conferences, so he gives his feedback on how this year’s virtual show compared to previous years.

What’s Hot In Gene Therapy

Erin Harris, chief editor of, reviews some of the hot cell and gene topics from 2020 and what to watch for in 2021. She also discusses the upcoming Cell & Gene live event and the miniseries she did for the Business of Biotech podcast.